Expression, purification and immunogenic characterization of hepatitis C virus recombinant E1E2 protein expressed by Pichia pastoris yeast

Antiviral Research

Volumn 88, Issue 1, 2010, Pages 80-85

  Cai, Weijia ^a   Su, Liya ^a   Liao, Qingjiao ^b   Ye, Linbai ^a   Wu, Yang ^b   Wu, Zhenghui ^a   She, Yinglong ^a  

^a WUHAN UNIVERSITY   (China)

^b WUHAN INSTITUTE OF VIROLOGY   (China)

Author keywords

Broadly neutralizing antibodies; Hepatitis C Virus (HCV); Pichia pastoris yeast; Recombinant E1E2 glycoprotein

Indexed keywords

CD81 ANTIGEN; NEUTRALIZING ANTIBODY; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN E1E2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANTIGEN BINDING; ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION SYSTEM; GENOTYPE; HEPATITIS C VIRUS; IMMUNIZATION; IMMUNOGENICITY; NONHUMAN; PICHIA PASTORIS; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; PROTEIN PURIFICATION; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEUTRALIZING; ANTIGENS, CD; ENZYME-LINKED IMMUNOSORBENT ASSAY; GENE EXPRESSION; GLYCOSYLATION; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; NEUTRALIZATION TESTS; PICHIA; PLASMIDS; RABBITS; RECOMBINANT PROTEINS; VIRAL ENVELOPE PROTEINS; VIRAL HEPATITIS VACCINES;

HEPATITIS C VIRUS; ORYCTOLAGUS CUNICULUS; PICHIA PASTORIS;

EID: 77956908351     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2010.07.007     Document Type: Article

References (29)

1. Broering T.J., Garrity K.A., Boatright N.K., Sloan S.E., Sandor F., Thomas W.D., Szabo G., Finberg R.W., Ambrosino D.M., Babcock G.J. Identification and characterization of broadly neutralizing human monoclonal antibodies directed against the E2 envelope glycoprotein of hepatitis C virus. J. Virol. 2009, 83:12473-12482.
2. Cocquerel L., Quinn E.R., Flint M., Hadlock K.G., Foung S.K.H., Levy S. Recognition of native hepatitis C virus E1E2 heterodimers by a human monoclonal antibody. J. Virol. 2003, 77:1604-1609.
3. Deleersnyder V., Pillez A., Wychowski C., Blight K., Xu J., Hahn Y.S., Rice C.M., Dubuisson J. Formation of native hepatitis C virus glycoprotein complexes. J. Virol. 1997, 71:697-704.
4. Eren R., Landstein D., Terkieltaub D., Nussbaum O., Zauberman A., Ben-Porath J., Gopher J., Buchnick R., Kovjazin R., Rosenthal-Galili Z., Aviel S., Ilan E., Shoshany Y., Neville L., Waisman T., Ben-Moshe O., Kischitsky A., Foung S.K.H., Keck Z.-Y., Pappo O., Eid A., Jurim O., Zamir G., Galun E., Dagan S. Preclinical evaluation of two neutralizing human monoclonal antibodies against hepatitis C virus (HCV): a potential treatment to prevent HCV reinfection in liver transplant patients. J. Virol. 2006, 80:2654-2664.
5. Falkowska E., Kajumo F., Garcia E., Reinus J., Dragic T. Hepatitis C virus envelope glycoprotein E2 glycans modulate entry, CD81 binding, and neutralization. J. Virol. 2007, 81:8072-8079.
6. Flint M., Logvinoff C., Rice C.M., McKeating J.A. Characterization of infectious retroviral pseudotype particles bearing hepatitis C virus glycoproteins. J. Virol. 2004, 78:6875-6882.
7. Hadlock K.G., Lanford R.E., Perkins S., Rowe J., Yang Q., Levy S., Pileri P., Abrignani S., Foung S.K. Human monoclonal antibodies that inhibit binding of hepatitis C virus E2 protein to CD81 and recognize conserved conformational epitopes. J. Virol. 2000, 74:10407-10416.
8. Han X., Ye L.-B., Li B.-z., Bo G., Cai W-j., Hong Z., She Y.-L., Li Y., Kong L.B., Wu Z.-H. Expression, purification and characterization of the hepatitis B virus entire envelope large protein in Pichia pastoris. Protein Expr. Purif. 2006, 49:168-175.
9. Helle F., Goffard A., Morel V., Duverlie G., McKeating J., Keck Z.-Y., Foung S., Penin F., Dubuisson J., Voisset C. The neutralizing activity of anti-hepatitis C virus antibodies is modulated by specific glycans on the E2 envelope protein. J. Virol. 2007, 81:8101-8111.
10. Houghton M., Abrignani S. Prospects for a vaccine against the hepatitis C virus. Nature 2005, 436:961-966.
11. Hsu M., Zhang J., Flint M., Logvinoff C., Cheng-Mayer C., Rice C.M., McKeating J.A. Hepatitis C virus glycoproteins mediate pH-dependent cell entry of pseudotyped retroviral particles. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:7271-7276.
12. Johansson D.X., Voisset C., Tarr A.W., Aung M., Ball J.K., Dubuisson J., Persson M.A. Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:16269-16274.
13. Keck Z.-Y., Sung V.M.H., Perkins S., Rowe J., Paul S., Liang T.J., Lai M.M.C., Foung S.K.H. Human monoclonal antibody to hepatitis C virus E1 glycoprotein that blocks virus attachment and viral infectivity. J. Virol. 2004, 78:7257-7263.
14. Keck Z.-Y., Xia J., Cai Z., Li T.-K., Owsianka A.M., Patel A.H., Luo G., Foung S.K. Immunogenic and functional organization of hepatitis C virus (HCV) glycoprotein E2 on infectious HCV virions. J. Virol. 2007, 81:1043-1047.
15. Lambot M., Frétier S., Op De Beeck A., Quatannens B., Lestavel S., Clavey V., Dubuisson J. Reconstitution of hepatitis C virus envelope glycoproteins into liposomes as a surrogate model to study virus attachment. J. Biol. Chem. 2002, 277:20625-20630.
16. Lauer G.M., Walker B.D. Hepatitis C virus infection. N. Engl. J. Med. 2001, 345:41-52.
17. Li B., Gao B., Ye L., Han X., Wang W., Kong L., Fang X., Zeng Y., Zheng H., Li S., Wu Z., Ye L. Hepatitis B virus X protein (HBx) activates ATF6 and IRE1-XBP1 pathways of unfolded protein response. Virus Res. 2007, 124:44-49.
18. Lindenbach B.D., Rice C.M. Flaviridae: the viruses and their replication. Fields Virology 2001, 41. Lippincott Williams & Wilkins, Philadelphia. D. Knipe, P.M. Howley (Eds.).
19. Martinez-Donato G., Acosta-Rivero N., Morales-Grillo J., Musacchio A., Vina A., Alvarez C., Figueroa N., Guerra I., Garcia J., Varas L., Muzio V., Dueñas-Carrera S. Expression and processing of hepatitis C virus structural proteins in Pichia pastoris yeast. Biochem. Biophys. Res. Commun. 2006, 342:625-631.
20. Morel N., Massoulié J. Expression and processing of vertebrate acetylcholinesterase in the yeast Pichia pastoris. Biochem. J. 1997, 328:121-129.
21. Op De Beeck A., Voisset C., Bartosch B., Ciczora Y., Cocquerel L., Keck Z., Foung S., Cosset F.L., Dubuisson J. Characterization of functional hepatitis C virus envelope glycoproteins. J. Virol. 2004, 78:2994-3002.
22. Owsianka A.M., Timms J.M., Tarr A.W., Brown R.J., Hickling T.P., Szwejk A., Bienkowska-Szewczyk K., Thomson B.J., Patel A.H., Ball J.K. Identification of conserved residues in the E2 envelope glycoprotein of the hepatitis C virus that are critical for CD81 binding. J. Virol. 2006, 80:8695-8704.
23. Pileri P., Uematsu Y., Campagnoli S., Galli G., Falugi F., Petracca R., Weiner A.J., Houghton M., Rosa D., Grandi G., Abrignani S. Binding of hepatitis C virus to CD81. Science 1998, 282:938-941.
24. XTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl. 2006, 12:1381-1389.
25. Tscherne D.M., Jones C.T., Evans M.J., Lindenbach B.D., McKeating J.A., Rice C.M. Time- and temperature-dependent activation of hepatitis C virus for low-pH-triggered entry. J. Virol. 2006, 80:1734-1741.
26. Wakita T., Pietschmann T., Kato T., Date T., Miyamoto M., Zhao Z., Murthy K., Habermann A., Kräusslich H.G., Mizokami M., Bartenschlager R., Liang T.J. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nat. Med. 2005, 11:791-796.
27. Stamataki Z., Coates S., Evans M.J., Wininger M., Crawford K., Dong C., Fong Y.-L., Chien D., Abrignani S., Balfe P., Rice C.M., McKeating J.A., Houghton M. Hepatitis C virus envelope glycoprotein immunization of rodents elicits cross-reactive neutralizing antibodies. Vaccine 2007, 25:7773-7784.
28. Zhang J., Randall G., Higginbottom A., Monk P., Rice C.M., McKeating J.A. CD81 is required for hepatitis C virus glycoprotein-mediated viral infection. J. Virol. 2004, 78:1448-1455.
29. Zhong J., Gastaminza P., Cheng G., Kapadia S., Kato T., Burton D.R., Wieland S.F., Uprichard S.L., Wakita T., Chisari F.V. Robust hepatitis C virus infection in vitro. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:9294-9299.